Zhengzhou Granlen PharmaTech is a multinational chemistry-based contract research organization that offers an integrated discovery and development platform for the biotech and pharmaceutical industries. Their state of the art research facilities and head office are located in Zhengzhou, China. The company also has offices in San Diego, California. Granlen's chemistry and related teams offer made to order compound libraries, hit-to-lead optimization, medicinal chemistry, and a wide range of chemistry-related services including custom synthesis, intermediates, reference compounds, metabolites and impurities, route scouting, process development, and scale-up as well as analytical method development, quality control, and others for investigational new drug preparation.
As of February 2020, clinical trials are ongoing to repurpose Zhengzhou Granlen PharmaTech's Azvudine drug, an experimental reverse transcriptase inhibitor drug against HIV-1/AIDS, to treat Covid-19.
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.